Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)

Taysha Gene Therapies, Inc.

CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.
Awards tied to clinical, regulatory, and corporate milestones by Dec 31, 2023; vest over 3 years.
Board revised director compensation: initial equity grant set at 43,800 shares; annual at 36,200 shares.
Options under 2020 Stock Incentive Plan; intended to strengthen pay-for-performance alignment.
No departure reported; grants are one-time performance-based equity incentives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.